Transtorno obsessivo-compulsivo no período perinatal
DOI:
https://doi.org/10.25118/2236-918X-8-1-4Palabras clave:
Tanstorno obsessivo-compulsivo, gravidez, período pós-partoResumen
O transtorno obsessivo-compulsivo (TOC) é um transtorno psiquiátrico relativamente comum no período perinatal. Nesse período, o TOC pode ser desencadeadoou pode ocorrer a exacerbação da doença pré-existente,com prevalências de até 9% de TOC no período pós-parto. Estima-se que haja uma associação com a flutuaçãodos hormônios gonadais, além da influência de outrosfatores psicológicos e sociais. A apresentação clínicado TOC parece diferir durante a gestação e o período pós-parto, existindo uma predominância de obsessõesde contaminação e compulsões por limpeza durantea gestação, enquanto que, no período pós-parto, os sintomas mais frequentemente encontrados na literatura científica foram as obsessões egodistônicas de conteúdo agressivo. Existem poucos estudos específicos sobre o tratamento do TOC no período perinatal, de forma quese recomenda seguir os protocolos de tratamento para a população geral, porém levando-se em consideração os potenciais efeitos adversos das medicações para o feto e/ou lactente. O presente artigo consiste em uma revisão narrativa acerca do TOC no período perinatal e tem como objetivo alertar os profissionais de saúde para a presença de sintomas obsessivos-compulsivos e do TOC nesse período, além de auxiliar o clínico a melhor reconhecer, compreender e tratar esse transtorno.
Descargas
Métricas
Citas
American Psychiatric Association. Obsessive-compulsive and related disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington: American Psychiatric Publishing; 2013. p. 235-64.
Sadock BJ, Sadock VA, Ruiz P. Transtorno obsessivo-compulsivo e transtornos relacionados. In: Sadock BJ, Sadock VA, Ruiz P. Compêndio de psiquiatria: ciências do comportamento e psiquiatria clínica. 11ª ed. Porto Alegre: Artmed; 2016. p. 418-36.
Russell EJ, Fawcett JM, Mazmanian D. Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. J Clin Psychiatry. 2013;74:377-85.
Zambaldi CF, Cantilino A, Montenegro AC, Paes JA, de Albuquerque TL, Sougey EB. Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. Compr Psychiatry. 2009;50:503-9.
Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry. 1997;58:330-4.
Labad J, Menchón JM, Alonso P, Segalàs C, Jiménez S, Vallejo J. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:428-35.
Guglielmi V, Vulink NC, Denys D, Wang Y, Samuels JF, Nestadt G. Obsessive–compulsive disorder and female reproductive cycle events: results from the OCD and reproduction collaborative study. Depress Anxiety. 2014;31:979-87.
Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN. Onset and exacerbation of obsessive-compulsive disorder in pregnancyand the postpartum period. J Clin Psychiatry. 2010;71:1061-8.
Uguz F, Kaya V, Gezginc K, Kayhan F, Cicek E. Clinical correlates of worseningin obsessive-compulsive symptoms during pregnancy. Gen Hosp Psychiatry. 2011;33:197-9.
Steiner M, Dunn E, Born L. Hormone and mood: from menarche to menopause and beyond. J Affect Disord 2003;74:67-83.
Bloch M, Rotenberg N, Koren D, Klein E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord. 2005;88:9-18.
Pedersen CA, Prange AJ Jr. Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci U S A. 1979;76:6661-5.
Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, et al. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette’s syndrome and healthy controls. Arch Gen Psychiatry 1994;51:782-92.
Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, et al. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology. 1994;19:723-49.
Fairbrother N, Abramowitz JS. New parenthood as a risk factor for the development of obsessional problems. Behav Res Ther. 2007;45:2155-63.
Woodward K. Motherhood identities, meanings and myths. In: Woodward K, editor. Identity and difference. London: SAGE; 1997. p. 239-98.
McGuinness M, Blissett J, Jones C. OCD in the perinatal period: is postpartum OCD (ppOCD) a distinct subtype? A review of the literature. Behav Cogn Psychother. 2011;39:285-310.
Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res. 1999;89:49-58.
House SJ, Tripathi SP, Knight BT, Morris N, Newport DJ, Stowe ZN. Obsessive-compulsive disorder in pregnancy and the postpartum period: course of illness and obstetrical outcome. Archs Womens Meant Health. 2016;19:3-10.
Uguz F, Gezginc K, Zeytinci IE, Karatayli S, Askin R, Guler O, et al. Obsessive-compulsive disorder in pregnant women during the third trimester of pregnancy. Compr Psychiatry. 2007;48:441-5.
Uguz F, Akman C, Kaya N, Cilli AS. Postpartum-onset obsessive compulsive disorder: incidence, clinical features and related factors. J Clin Psychiatry. 2007;68:132-8.
Diaz SF, Grush LR, Sichel DA, Cohen LS. Obsessive-compulsive disorder in pregnancy and the puerperium. In: Dicstein LJ, Riba MB, Oldham JM, editors. Review of psychiatry. Washington: American Psychiatric Press; 1997. Vol 16. p. 97-112.
Sichel DA, Cohen LS, Rosenbaum JF, Driscoll J. Postpartum onset of obsessive-compulsive disorder. Psychosomatics. 1993;34:277-9.
Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF. Postpartum obsessivecompulsive disorder: a case series. J Clin Psychiatry. 1993;54:156-9.
Rachman S, de Silva P. Abnormal and normal obsessions. Behav Res Ther. 1978;16:233-48.
Salkovskis PM, Harrison J. Abnormal and normal obsessions—a replication. Behav Res Ther. 1984;22:549-52.
Purdon C, Clark DA. Obsessive intrusive thoughts in nonclinical subjects. Part I. Content and relation with depressive, anxious and obsessional symptoms. Behav Res Ther. 1993;31:713-20.
Christian LM, Storch EA. Cognitive behavioral treatment of postpartum onset: obsessive compulsive disorder with aggressive obsessions. Clin Case Stud. 2009;8:72-83.
Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessive-compulsive symptoms in pregnancy and puerperium: a review of literature. J Anxiety Disord. 2003;17:461-78.
Sjöström K, Valentin L, Thelin T, Marsál K. Maternal anxiety in late pregnancy and fetal hemodynamics. Eur J Obstet Gynecol Reprod Biol. 1997;74:149-55.
Sanchez SE, Puente GC, Atencio G, Qiu C, Yanez D, Gelaye B, et al. Risk of spontaneous pretermbirth in relation to maternal depressive, anxiety and stress symptoms. J Reprod Med. 2013;58:25-33.
Loomans EM, van der Stelt O, van Eijsden M, Gemke RJ, Vrijkotte T, den Bergh BR. Antenatal maternal anxiety is associated with problem behaviour at age five. Early Hum Dev. 2011;87:565-70.
Buss C, Davis EP, Hobel CJ, Sandman CA. Maternal pregnancy specific anxiety is associated with child executive function at 6-9 years age. Stress. 2011;14:665-76.
Leis JA, Heron J, Stuart EA, Mendelson T. Associations between maternal mental health and child emotional and behavioral problems: does prenatal mental health matter? J Abnorm Child Psychol. 2014;42:161-71.
Talge NM, Neal C, Glover V; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on
Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry. 2007;48:245-61.
Ding XX, Wu YL, Xu SJ, Zhu RP, Jia XM, Zhang SF, et al. Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies. J Affect Disord. 2014;159:103-10.
Van Batenburg-Eddes T, Brion MJ, Henrichs J, Jaddoe VW, Hofman A, Verhulst FC, et al. Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study. J Child Psychol Psychiatry. 2013;54:591-600.
Uguz F, Onder Sonmez E, Sahingoz M, Gokmen Z, Basaran M, Gezginc K, et al. Neuroinflammation in the fetus exposed to maternal obsessive-compulsive disorder during pregnancy: a comparative study on cord blood tumor necrosis factor-alpha levels. Compr Psychiatry. 2014;55:861-5.
Lan X, Chen Q, Wang Y, Jia B, Sun L, Zheng J, et al. TNF-a affects human cortical neural progenitor cell differentiation through the autocrinesecretion of leukemia inhibitory factor. PLoS One. 2012;7:e50783.
LaSalle VH, Cromer KR, Nelson KN, Kazuba D, Justement L, Murphy DL. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depress Anxiety. 2004;19:163-73.
Tükel R, Polat A, Ozdemir O, Aksüt D, Türksoy N. Comorbid conditions in obsessive-compulsive disorder. Compr Psychiatry. 2002;43:204-9.
Denys D, Tenney N, van Megen HJ, de Geus F, Westenberg HG. Axis I and II comorbidity in a large sample of patients with obsessive compulsive disorder. J Affect Disord. 2004;80:155-62.
Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, Marin-Martinez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008;28:1310-25.
Jonsson H, Hougaard E. Group cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysis. Acta Psychiatr Scand. 2009;119:98-106.
Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007;(2):CD005333.
Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011;11:200.
Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69:621-32.
Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P. Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? Depress Anxiety. 2011;28:560-7.
Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997;65:44-52.
Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysisof psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24:1011-30.
Noordik E, van der Klink JJ, Klingen EF, Nieuwenhuijsen K, van Dijk FJ. Exposure-in-vivo containing interventions to improve work functioning of workers with anxiety disorder: a systematic review. BMC Public Health. 2010;10:598.
Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151-61. 53. Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;52:987-97.
Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165:621-30.
Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004;19:225-33.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14:S1.
Marchesi C, Ossola P, Amerio A, Daniel BD, Tonna M, De Panfilis C. Clinical management of perinatal anxiety disorders: a systematic review. J Affect Disord. 2016;190:543-50.
Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127:94-114.
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31:403-13.
Uguz F. Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach. Rev Bras Psiquiatr. 2015;37:334-42.
Ross LE, McLean ML. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry. 2006;67:1285-98.
MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61:588-603.
Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressantmedication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436-43.
Jefferies AL; Canadian Paediatric Society, Fetus and Newborn Committee. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes. Paediatr Child Health. 2011;16:562-3.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.
Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88:159-70.
Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnancy and postpartum women. Annu Rev Clin Psychol. 2014;10:369-92.
Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selectivserotonin reuptake inhibitor medicati ons and congenital malformati ons. Aust N Z J Psychiatry. 2013;47:1002-12.
Kellner M. Drug treatment of obsessive- compulsive disorder. Dialogues Clin Neurosci. 2010;12:187-97.
Genti le S. Tricyclic anti depressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014;13:207-25.
Källén B, Ott erblad Olausson P. Anti depressant drugs during pregnancy and infant congenital hearth defects. Reprod Toxicol. 2006;21:221-2.
Källén BA1, Ott erblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defects. Reprod Toxicol. 2003;17:255-61.
Denys D, van der Wee N, van Megen HJ, Westenberg HG. A doublen blind comparison of venlafaxine and paroxeti ne in obsessive compulsive disorder. J Clin Psychopharmacol. 2003;23:568-75.
Albert U, Aguglia E, Maina G, Bogett o F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63:1004-9.
Uguz F. Pharmacotherapy of obsessive-compulsive disorder during breastf eeding. Am J Ther. 2016 Sep 19. [Epub ahead of print]. doi: 10.1097/MJT.0000000000000500.
Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastf eeding: a systemati c review. Hum Psychopharmacol. 2015;30:4-20.
Chad L, Pupco A, Bozzo P, Koren G. Update on anti depressant use during breastf eeding. Can Fam Physician. 2013;59:633-4.
Pati l AS, Kuller JA, Rhee EH. Anti depressants in pregnancy: a review of commonly prescribed medicati ons. Obstet Gynecol Surv. 2011;66:777-87.
Genti le S. Use of contemporary anti depressants during breastf eeding: a proposal for a safety index. Drug Saf. 2007;30:107-21.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Debates em Psiquiatria permite que el (los) autor (es) mantenga(n) sus derechos de autor sin restricciones. Permite al (los) autor (es) conservar sus derechos de publicación sin restricciones. Los autores deben garantizar que el artículo es un trabajo original sin fabricación, fraude o plagio; no infringe ningún derecho de autor o derecho de propiedad de terceros. Los autores también deben garantizar que cada uno atendió a los requisitos de autoría conforme a la recomendación del ICMJE y entienden que, si el artículo o parte de él es fallido o fraudulento, cada autor comparte la responsabilidad.
Reconocimiento-NoComercial 4.0 internacional (CC BY-NC 4.0) - Debates em Psiquiatria es regida por la licencia CC-BY-NC
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia. Bajo las condiciones siguientes:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
